Arthritis/rheumatic disorders:
Indications for: AZASAN
To reduce signs/symptoms of active rheumatoid arthritis; may be used with aspirin, NSAIDs, and/or low dose corticosteroids.
Adult Dosage:
Initially: 1mg/kg (50mg–100mg) daily in 1–2 divided doses; after 6–8 wks, if needed, may increase by 0.5mg/kg daily increments every 4-weeks. Max: 2.5mg/kg per day. Maintenance: use lowest effective dose.
Children Dosage:
Not recommended.
AZASAN Contraindications:
Pregnancy (Cat.D). Prior treatment with alkylating agents (eg, cyclophosphamide, chlorambucil, melphalan, or others) may increase risk of neoplasia.
AZASAN Warnings/Precautions:
Be fully familiar with product's toxicity before use. Risk of myelotoxicity with low or absent thiopurine S-methyl transferase (TPMT) activity. Monitor blood. Impaired renal function. Discontinue if ineffective after 12 weeks. Nursing mothers: not recommended.
AZASAN Classification:
Immunosuppressant.
AZASAN Interactions:
Reduce dose to ⅓ or ¼ with allopurinol. TPMT enzyme inhibition with aminosalicylates (eg, sulphasalazine, mesalazine, olsalazine). Leukopenia with co-trimoxazole. Anemia, leukopenia with ACE Inhibitors. May antagonize warfarin.
Adverse Reactions:
Severe leukopenia and/or thrombocytopenia, macrocytic anemia, pancytopenia, severe bone marrow suppression, GI disturbances, secondary infections, mutagenic and carcinogenic potential, hepatotoxicity, rash.
Generic Drug Availability:
YES
How Supplied:
Tabs—100
Organ rejection prophylaxis:
Indications for: AZASAN
Adjunct for the prevention of rejection in renal homotransplantation.
Adult Dosage:
Start at time of transplant or 1–3 days prior; usually with IV formulation. Initially: 3–5 mg/kg daily. Maintenance: 1–3mg/kg daily.
Children Dosage:
Not recommended.
AZASAN Contraindications:
Pregnancy (Cat.D).
AZASAN Warnings/Precautions:
Be fully familiar with product's toxicity before use; consider discontinuing if severe toxicity occurs. Risk of myelotoxicity with low or absent thiopurine S-methyl transferase (TPMT) activity. Monitor blood. Impaired renal function. Nursing mothers: not recommended.
AZASAN Classification:
Immunosuppressant.
AZASAN Interactions:
Reduce dose to ⅓ or ¼ with allopurinol. TPMT enzyme inhibition with aminosalicylates (eg, sulphasalazine, mesalazine, olsalazine). Leukopenia with co-trimoxazole. Anemia, leukopenia with ACE Inhibitors. May antagonize warfarin.
Adverse Reactions:
Severe leukopenia and/or thrombocytopenia, macrocytic anemia, pancytopenia, severe bone marrow suppression, GI disturbances, secondary infections, mutagenic and carcinogenic potential, hepatotoxicity, rash.
Generic Drug Availability:
YES
How Supplied:
Tabs—100
